Table 2 Comparison of treatment groups across clinical and radiologic outcomes in the interval between 3 and 15Â months after treatment initiation
From: Comparison of dimethyl fumarate and interferon outcomes in an MS cohort
| Â | IFNb-1a | DMF | ORa (95% CI) |
|---|---|---|---|
Number (%) of subjects with a relapse | 24 (24.5) | 21 (9.6) | 3.04 (1.60, 5.79) |
Number (%) of subjects with a new lesion on brain MRI | 28 (28.6) | 19 (8.7) | 4.19 (2.20, 7.97) |
Number (%) of subjects with a new GD + lesion on brain MRI | 12 (12.2) | 12 (5.5) | 2.40 (1.04, 5.54) |
Number (%) of subjects with new T2 lesion on brain MRI | 26 (26.5) | 17 (7.8) | 4.27 (2.19, 8.33) |
Number (%) of subjects with sustained disease progression | 8 (8.9) | 12 (5.6) | 1.64 (0.65, 4.17) |
Number (%) of subjects with no relapse, new MRI lesion or sustained progression (NEDA) | 46 (51.1) | 171 (79.9) | 0.26 (0.15, 0.45) |
| Â | Â | Â | RR (95% CI)b |
Annualized relapse rate | 0.29 | 0.11 | 2.49 (1.40, 4.44) |